Boston Scientific announced it has received Pharmaceuticals and Medical Device Agency approval in Japan for the FARAPULSE Pulsed Field Ablation System. The FARAPULSE PFA System, which is indicated for the isolation of pulmonary veins in the treatment of paroxysmal atrial fibrillation, is a novel alternative to standard-of-care thermal ablation treatment. Boston Scientific plans to launch the FARAPULSE PFA System in Japan in the coming weeks, following reimbursement approval.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific closes acquisition of Silk Road Medical
- Boston Scientific: FDA approves expanded indication of INGEVITY+ Pacing Leads
- Boston Scientific participates in a conference call with Piper Sandler
- Election 2024: Where To Put Your Money Ahead of the Vote
- Boston Scientific price target raised to $94 from $91 at Raymond James